Modality
ERT
MOA
MALT1i
Target
AuroraA
Pathway
JAK/STAT
Crohn'sRBCTCL
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
Aug 2020
→ Feb 2030
Phase 1Current
NCT06642608
1,093 pts·RB
2020-08→2030-02·Terminated
1,093 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-113.9y awayInterim· RB
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Termina…
Catalysts
Interim
2030-02-11 · 3.9y away
RB
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06642608 | Phase 1 | RB | Terminated | 1093 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ARG-6988 | Argenx | Preclinical | AuroraA |